RNC Pharma: import of drugs for clinical trials peaked

The total volume of shipments of drugs for clinical investigations (CI) to Russia totaled in the period January-June 2020 12.2 billion rubles. Dynamics of the ruble compared to the same period 2019 reached 49%. Analysts RNC Pharma emphasized that over the past year has grown not only monetary, but also natural imports, dynamics in packages made up in the 1st half of 2020 40%, since the beginning of the year, Russia imported 472 thousand packages of drugs for KI.

During the period Russia imported 505 of the names of the investigated drugs is on the 61st place more than a year earlier. From the total list of supplies 181 trademark imported in the form of a placebo, in the 1st half of 2019 preparations are imported only under 155 brands. While the share of natural preparations placebo in total imports over the past year has decreased significantly, from 40% to 34%. It is important that the volume of ruble supply placebo increased from 16% to 18%.

Among the new investigational drugs, deliveries of which started from the 2nd quarter of 2020, the maximum monetary amount of imports are serpertine company “Eli Lilly”. Parallel now carried out two studies are both multicenter randomized open phase III studies in which a comparison of the drug with alternative treatment regimens in patients with progressing common medullary thyroid cancer, as well as in the case of advanced or metastatic non-small cell lung cancer. The study involved 16 clinical centers involving 46 patients. Research permits the company received in February 2020, the actual deliveries began in April 2020.